Healthcare Professionals
Learn more about the latest in technological innovations to ablate, necrotize or coagulate soft tissue in the brain.
Patients & Caregivers
Find out more about minimally invasive brain surgery technology for you or your loved one.
NEUROBLATE® SYSTEM
NeuroBlate® is the only minimally invasive, robotic, laser thermal therapy tool that uses MRI-guided surgical ablation technology designed specifically for use in the brain.
The Minimally Invasive Surgical Choice
NeuroBlate provides precise and maximal brain lesion ablation for patients without the invasiveness of an open neurosurgical procedure. The precise nature of the procedure helps lessen the likelihood of harm to nearby healthy tissue.1
NeuroBlate offers hope and healing to patients suffering from a wide range of neurological lesions, including brain tumors, radiation necrosis, and epileptic foci.
EXCLUSIVE TECHNOLOGIES
NeuroBlate delivers a comprehensive, full solution laser ablation system that includes software, disposables, and hardware.
TruTemp™ Technology
Provides confidence in the accuracy of the ablation zone and added safety assurance.
NeuroBlate Fusion™ Software
Allows neurosurgeons to plan, deliver, and monitor MRI-guided robotic laser thermal therapy.
NeuroBlate Optic™ Laser Probe
The first and only commercially available laser probe with fiber optic controlled cooling.
CLINICAL RESEARCH & TRIALS
Our commitment to clinical research is an essential and integral part of our mission and is demonstrated in our clinical trial work.
Active Clinical Trials
The Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System (LAANTERN) Prospective Registry is currently enrolling eligible patients.
LITT Evidence
The cumulative utilization of LITT over time has been steadily increasing for metastatic tumor, primary tumor, radiation necrosis, and epileptic foci.
FIND A PHYSICIAN
A Minimally Invasive Surgical Option
To locate physicians currently using the NeuroBlate System, please click here.
Please note, NeuroBlate is available in the U.S. and Canada only.
RECENT NEWS
Monteris Medical Announces Publication of Largest Cohort to Date of LITT for Treating Most Aggressive Brain Tumor
Monteris Medical announced today that a paper on laser interstitial thermal therapy (LITT) for patients diagnosed with IDH wild-type glioblastoma, the most common and aggressive tumor originating in the brain, has been published in the journal, Neuro- Oncology Advances. The data on 89 patients collected through the LAANTERN prospective, multi-center registry, showed that LITT offers an effective alternative to traditional surgery for patients with newly diagnosed and recurrent glioblastoma while also delivering the benefits of a minimally invasive surgical procedure, including short recovery time and reduced potential for side effects.
Monteris Medical Announces Study Published on Patient Preferences for Drug-Resistant Epilepsy Treatment Options
Monteris Medical announced today that a study on patient preferences for treating drug-resistant epilepsy (DRE) has been published in the peer-reviewed journal, Epilepsy and Behavior.
Monteris Medical Announces Positive Coverage Policy Decision for MR-guided Laser Interstitial Thermal Therapy
Monteris Medical, the leader in MR-guided laser interstitial thermal therapy (LITT or laser ablation), announced today that Cigna, a global health services company and one of the largest commercial payors in the United States, has released a national coverage policy supporting the use of LITT for people with brain tumors and drug-resistant epilepsy.
- Rennert RC, Khan U, Barktek J Jr et al. Laser Ablation of Abnormal Neurological Tissue Using Robotic Neuroblate System (LAANTERN): procedural safety and hospitalization. Neurosurgery. published online: May 11, 2019. (doi: 10.1093/neuros/nyz141)